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A B S T R A C T
Objectives: NDM-producing Enterobacteriaceae are considered emergent on the African continent and
have been increasingly reported in recent years. In contrast, strains producing NDM-type enzymes have
been rarely reported in Italy, usually associated with sporadic cases or small outbreaks. Here we report
two cases of infection caused by NDM-1-producing Klebsiella pneumoniae (NDM-KP) in two unrelated
patients returned from travel to Egypt.
Case reports: The two patients had been previously hospitalised for a short period in two different
Egyptian hospitals. In our institution in Italy, NDM-KP isolates were detected from surgical wound
drainage (patient #1) and respiratory secretions and blood cultures (patient #2). Rectal swabs of both
patients were persistently positive for NDM-KP. In both cases, NDM-1-producing isolates exhibited a
multidrug-resistant phenotype, being susceptible only to tigecycline and colistin. Analysis by multilocus
sequence typing (MLST) revealed that the two K. pneumoniae isolates were not clonally related, belonging
to different sequence types (STs), namely ST15 from patient #1 and ST11 from patient #2.
Conclusions: To the best of our knowledge, this is the first report of NDM-producing isolates imported
from Africa to Italy, with no obvious link to the Indian subcontinent. Our experience confirms that Egypt
is an emergent source of NDM-producing Enterobacteriaceae, thus representing a cause of concern for
Mediterranean countries. Owing to its geographical position, Italy is a first-line European checkpoint
with respect to African countries and plays a pivotal role in limiting the dissemination of high-risk clones,
especially considering the latest strong migration flows.
© 2016 Published by Elsevier Ltd on behalf of International Society for Chemotherapy of Infection and
Cancer.
1. Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) have become a
worldwide health issue and pose a major threat due to the
narrowing range of therapeutic options [1]. In most cases,
resistance is due to carbapenemase production and affects
Klebsiella pneumoniae strains. New Delhi metallo-b-lactamase-1
(NDM-1) was first described in 2008 in a K. pneumoniae isolate
from a Swedish patient who had previously been hospitalised in
New Delhi, India [2]. It is a class B carbapenemase that is able to
confer resistance to almost all b-lactams, except the monobactam
aztreonam. Of note, owing to the co-presence of other resistance
mechanisms, NDM-producing isolates are usually also resistant to
aminoglycosides, fluoroquinolones and sulphonamides, leaving
few or no therapeutic options [1]. Following the first description,
NDM-type enzymes have been detected in different strains from all
continents, and several variants have been identified (NDM-1 to
-14) [1,3]. The Indian subcontinent, the Balkan region and the
Middle East are considered to be the main endemic areas for NDM-
producers [4]. Focusing on the African continent, the first
identification of NDM-1 occurred in 2007 in a K. pneumoniae
strain obtained from the urinary tract of a patient hospitalised in
Kenya [5]. NDM-producing Enterobacteriaceae have been subse-
quently reported from several African nations and have been* Corresponding author. Fax: +39 0341 489 601.
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increasingly described in recent years [6]. In Europe, a significant
spread, although more limited than the Indian subcontinent, was
also observed in the UK, which has close ties with India and
Pakistan [7]. In Italy, the first detection of NDM-1 occurred in
2009, in two patients hospitalised in Modena (northern Italy) and
colonised at the intestinal level by a NDM-1-producing Escher-
ichia coli. Analysis of hospital records revealed an epidemiological
link between these two cases and a third patient with a history of
hospital admission in India (in 2008). The latter patient had faecal
carriage of carbapenem-resistant E. coli during a stay in the same
unit in the same period [8]. Two years later, in 2011, NDM-1 was
detected in K. pneumoniae and E. coli isolates obtained from six
patients hospitalised in four healthcare facilities in the Bologna
area (northern Italy, close to Modena), with one patient having a
history of hospitalisation in New Delhi, India [9]. More recently, in
2012, the NDM-4 variant was detected in E. coli from two patients
hospitalised in a ward of a large tertiary healthcare facility in
Genoa (northern Italy). Also in this case, one of the patients had
been previously hospitalised in India [10]. This kind of
epidemiology highlights the pivotal role of the Indian subconti-
nent in the worldwide dissemination of NDM-producing isolates.
In particular, patients repatriated after hospitalisation abroad
may be a risk for introducing multidrug-resistant micro-
organisms into hospitals in their home countries.
Here we report two cases of infection caused by NDM-1-
producing K. pneumoniae in two patients returned from travel to
Egypt, where they had also been hospitalised. To the best of our
knowledge, this is the first report of infections caused by NDM-1-
producing isolates imported from Africa to Italy.
2. Case reports
2.1. Case #1
On 3 April 2014, a 2-year-old Italian child of African origin
was involved in a traffic accident during a holiday in Egypt and
was hospitalised in an intensive care unit (ICU) at a hospital in
Cairo. Radiological examination evidenced abdominal crushing,
pelvic fracture, hepatic laceration and spleen contusion. The
child underwent abdominal surgery by laparotomy with partial
hepatectomy and the placement of subhepatic drainage. No
data on the antibiotic regimen during this hospitalisation
period are available. On 8 April 2014, he returned to Italy with
the family and on 11 April 2014 was admitted to our institution
(A. Manzoni Hospital, Lecco, Italy) with an extended abdominal
haematoma, diffuse bruises and a surgical abdominal wound
with loss of peritoneal fluid as a consequence of the drainage.
On admission, he had fever and abdominal pain. The drainage
fluid and a rectal swab for screening of CRE were taken for
laboratory analysis. Empirical antimicrobial  therapy based on
ampicillin (500 mg four times daily) plus netilmicin [50 mg
once daily (o.d.)] was administered. Topical gentamicin was
applied to the surgical wound. Cultures both from the
rectalswab and the drainage fluid revealed the presence of a
carbapenem-resistant K. pneumoniae isolate. On 16 April 2014, the
child was transferred to the Paediatric Surgery Unit of another
hospital for surgical examination, but no surgical operation was
conducted. Hewas discharged on 29 April 2014, but 2 days later the
child was re-admitted to our hospital for abdominal pain and
vomiting syndrome, likely related to his surgical condition. During
hospitalisation he underwent radiological and microbiological
examination. Cultures were negative for common faecal patho-
gens (Salmonella, Shigella and Campylobacter), whilst the rectal
swab was again positive for carbapenem-resistant K. pneumoniae.
The child was discharged on 6 May 2014 in good condition. Ta
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2.2. Case #2
On 17 October 2014, a 63-year-old Italian citizen developed an
acute respiratory syndrome during a cruise on the Red Sea and was
hospitalised at the Red Sea Hospital (Hurghada, Egypt). On
admission he was soporose, with fever (41 !C), dyspnoea and
respiratory failure. An empirical antibiotic treatment was initiated
using meropenem [1 g three times daily (t.i.d.)], vancomycin [1 g
twice daily (b.i.d.)], metronidazole (500 mg t.i.d.) and fluconazole
(400 mg o.d.). Cultures of respiratory secretions revealed the
presence of Streptococcus pneumoniae. Because of this severe
clinical condition, the patient was intubated for mechanical
ventilation. On 20 October 2014, the patient was transferred to
the ICU of our institution in a very critical condition, with fever,
septic shock, respiratory failure, ischaemic cardiopathy and atrial
fibrillation. Intubation for mechanical ventilation as well as a
central venous catheter (CVC) were present at admission. His urine
was positive for pneumococcal urinary antigen, and therapy was
started with ceftriaxone (1 g b.i.d.), meropenem (1 g t.i.d.) and
levofloxacin (500 mg b.i.d.). Cultures of purulent respiratory
secretions (carried out on the first day of hospitalisation) were
positive for carbapenem-resistant K. pneumoniae, carbapenem-
resistant Acinetobacter baumannii and Stenotrophomonas malto-
philia. In addition, the CVC (previously placed in Egypt) was
positive for carbapenem-resistant A. baumannii. Based on these
findings, colistin (2 MU t.i.d.) and trimethoprim/sulfamethoxazole
(20 mg/kg o.d.) were added to therapy. On 12 November 2014,
blood cultures resulted positive for carbapenem-resistant K.
pneumoniae. Screening rectal swabs were positive for carbape-
nem-resistant K. pneumoniae and A. baumannii during the entire
hospitalisation period. On 3 December 2014, he was transferred to
the medical ward. Urine cultures were positive for carbapenem-
resistant K. pneumoniae on 5 and 15 December 2014, but no
antibiotic therapy was administered. The patient was discharged in
good condition on 19 December 2014.
Clinical information about the two case reports is summarised
in Table 1.
In both cases, bacterial identification was performed by matrix-
assisted laser desorption/ionisation time-of-flight mass spectrom-
etry (MALDI-TOF/MS) (VITEK1 MS; bioMérieux, Marcy-l’Étoile,
France). Antimicrobial susceptibility testing against the carbape-
nem-resistant K. pneumoniae was performed by the Clinical and
Laboratory Standards Institute (CLSI) broth microdilution refer-
ence method using lyophilised custom plates (Sensititre; Thermo-
Fisher Scientific, Basingstoke, UK) and the results were interpreted
according to European Committee on Antimicrobial Susceptibility
Testing (EUCAST) criteria [11]. Carbapenem-resistant K. pneumoniae
isolates were susceptible only to tigecycline and colistin (Table 2).
The presence of a metallo-b-lactamase (MBL) was phenotypically
evaluated on the basis of synergistic activity between meropenem
and dipicolinic acid using both the double disk approximation test
(Rosco Diagnostica A/S, Taastrup, Denmark) and a commercially
available combination method (KPC + MBL Confirm ID Kit; Rosco
Diagnostica A/S).
The blaNDM gene of both isolates was first detected by the
GeneXpert1 System using the Xpert Carba-R test (Cepheid,
Sunnyvale, CA). Conventional PCR and sequencing for confirmation
were performed as previously described [8,12] and revealed the
blaNDM-1 allelic variant. Multilocus sequence typing (MLST) was
carried out according to protocols and conditions as described on
the K. pneumoniae MLST website (http://bigsdb.web.pasteur.fr/
klebsiella/klebsiella.html). MLST analysis revealed that the two K.
pneumoniae isolates were not clonally related, belonging to two
different STs, namely ST15 in patient #1 and ST11 in patient #2.
Carbapenem-resistant A. baumannii from patient #2 was negative
for the blaNDM gene.
3. Discussion and conclusions
The global spread of NDM-type carbapenemases is a serious
threat in the field of carbapenem resistance because of rapid
dissemination and association with multidrug resistance that
greatly limits therapeutic options. To date, the reservoir of this
carbapenemase was mostly related to the Indian subcontinent,
which is inhabited by the second largest population in the world
and where NDM-1-producers are reported also for community-
acquired infections [4]. The size of that reservoir may explain the
rapidity of the worldwide dissemination of NDM-producers [4].
According to this context, all previously described NDM-producing
Enterobacteriaceae isolated in Italy were epidemiologically con-
nected to a history of hospitalisation on the Indian subcontinent
[8–10]. Interestingly, here we describe the first finding of NDM-
producing isolates imported from Africa to Italy, with no obvious
link to the Indian subcontinent. In these cases, in fact, NDM-1-
producing K. pneumoniae were already present at admission and
showed a strong correlation with recent previous hospitalisation in
Egyptian hospitals. Overall, limited information is available for this
geographic area, although NDM determinants have been previ-
ously described in K. pneumoniae, Pseudomonas aeruginosa and A.
baumannii isolated in Egypt [6,12,13]. Our data confirm that this
area is an emergent source of NDM-producing Enterobacteriaceae,
thus representing a cause of concern for Mediterranean countries.
Table 2
Antimicrobial resistance profile of NDM-1-producing Klebsiella pneumoniae isolates.
Antibiotic MIC (mg/L) [susceptibility categorya]
NDM-KP isolate from patient #1 NDM-KP isolate from patient #2
Amoxicillin/clavulanic acid >16 [R] >16 [R]
Piperacillin/tazobactam >64 [R] >64 [R]
Cefotaxime >32 [R] >32 [R]
Ceftazidime >32 [R] >32 [R]
Cefepime >32 [R] >32 [R]
Ertapenem >4 [R] >4 [R]
Imipenem 16 [R] 16 [R]
Meropenem 16 [R] 32 [R]
Amikacin >32 [R] >32 [R]
Gentamicin >8 [R] >8 [R]
Ciprofloxacin >4 [R] >4 [R]
Tigecycline 1 [S] 0.5 [S]
Trimethoprim/sulfamethoxazole >8 [R] >8 [R]
Colistin "0.5 [S] "0.5 [S]
MIC, minimum inhibitory concentration; R, resistant; S, susceptible.
a Results were interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria [11].
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The uncontained spread of carbapenemase-producing bacteria
may occur in Africa for several reasons, primarily owing to the
limited attention to antimicrobial stewardship and the suboptimal
level of infection control practices, with limited opportunity for
patient isolation or screening of high-risk individuals [6]. Of
concern, there is an increase in over-the-counter use of carbape-
nems in Africa, especially in Egypt, owing to the quasi-absence of
regulations governing antibiotic use [14].
In Italy, a recent countrywide surveillance showed that KPC-
producing enterobacteria are now endemic in this country,
whereas other carbapenemases (e.g. MBLs and OXA-type enzymes)
are sporadic and are responsible for a small percentage of cases
[15]. In our experience, early detection of NDM-producing isolates
was performed by rectal swab screening on admission based on
phenotypic and molecular methods. Further analysis by MLST
evidenced the presence of two different STs, of which ST15 has
been previously reported in Africa (Morocco) and belongs to CC14.
It is considered to be endemic both in Hungary and Denmark and
has been associated with a high content of virulence factors [16].
ST11 is the major ST among K. pneumoniae strains harbouring
blaKPC from Asia, but it has been also associated with NDM
determinants [17]. Of note, the first NDM-1-producing K. pneumo-
niae reported from Egypt belonged to ST11, and isolates of this type
have recently been found in the same country [18,19]. Both NDM-
1-producing isolates exhibited a multidrug-resistant phenotype,
being susceptible only to tigecycline and colistin. Of note, patient
#1 was not appropriately treated for NDM-producing K. pneumo-
niae. However, the patient’s conditions improved, thus suggesting
probable colonisation by NDM-producing K. pneumoniae rather
than infection. In contrast, patient #2 received an appropriate
antimicrobial regimen based on several extended-spectrum anti-
biotics given during the hospitalisation period in the ICU. As shown
in Fig. 1, colistin was administered for a long period of time
(38 days), mostly in combination with carbapenems (imipenem for
30 days and meropenem for 10 days). Following a 3-week
antimicrobial regimen, a 1-day treatment washout was applied
thus allowing the emergence of pathogens causing bloodstream
infection. Following a new course of antimicrobials, the patient
was discharged in good conditions after 61 days of hospitalisation.
The link between NDM acquisition and healthcare exposure
abroad has been extensively described [1,4]. This situation
necessitates a series of infection control measures as soon as
possible. At a local level, patients with a history of travel or
originating from high-risk countries should be screened for NDM-
producing bacteria [20]. Notably, the patients in the current study
were isolated on admission owing to their previous hospitalisation
in a country considered at-risk for CRE and were screened by rectal
swabs. This procedure in combination with the early detection of
NDM determinants prevented the development of onward
transmission and potential outbreaks and helped to optimise
antibiotic therapy. No further cases occurred in the hospital
setting. Limiting patient infections and surveillance of patients
colonised with carbapenemase-producing Enterobacteriaceae are
of paramount importance to hospital epidemiology and patient
safety. In this context, optimal therapeutic options are very limited.
Early recognition of carbapenemase expression is the key for
appropriate treatment. Ensuing availability of drugs based on
specific carbapenemase inhibitors (e.g. ceftazidime/avibactam,
which is not effective against class B carbapenemases) is a new
reason for precise identification of carbapenem resistance
determinants. Finally, it is worth noting that Italy is subject to
strong migration flows from African nations and plays a pivotal
role in limiting the dissemination of high-risk clones among
European countries.
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